enfortumab,Pembrolizumab,cisplatin,carboplatin,gemcitabine
Astellas,Merck,Seagen
['bladder', 'kudos', 'pembro']
phenomenal job by presenting phenomenal data for the combination of #endortumab #pembrolizumab in cis-ineligible #bladdercancer. amazing to see data holding with 4-year follow-up! kudos to the investigators. #asco23 
@cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.